The DOI matches its Crossref record.
Executive Summary
Open accessAbstract
As of September 1997, the Food and Drug Administration (FDA) requested the voluntary withdrawal from the market of dexfenfturarnine and fenfturamine due to a reported association between valvular disease and the use of dexfenfturamine or fenfturamine alone or combined with phentermine.The use of these drugs for weight reduction, therefore, is not recommended in this report.Sibutramine is approved by FDA for long-term use.It has limited but definite effects on weight loss and can facilitate weight loss maintenance.(Note: FDA approval for orlistat is pending a resolution of labeling issues and results of Phase III trials.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This recommendation is based on short-term studies showing numerous benefits of weight loss, including improvements in glycemic control, cardiovascular disease risk factors, quality of life and other obesity-related comorbidities.2”
From Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes (2013) · cites this paper as [2]
Experimental — accuracy not yet measuredIn the citing paper
“Its cutpoints for abdominal obesity came from the definition in the 1998 National Institutes of Health obesity clinical guidelines 108 ; they were a waist circumference of Ն102 cm (Ն40 in) for men and Ն88 cm (Ն35 in) for women.”
From Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement (2005) · cites this paper as [108]
In the citing paper
“Both weight reduction and maintenance of a lower weight are best achieved by a combination of reduced caloric intake and increased physical activity and the use of principles of behavior change.”
From Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement (2005) · cites this paper as [108]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Sorted by citations
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000107251.49515.c2 · Cited by 13,271
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437739.71477.ee · Cited by 2,735
Metadata
- Venue
- Obesity Research
- Publisher
- Wiley
- Published
- 1998-09
- Volume
- 6
- Issue
- S2
- ISSN
- 1071-7323 (ISSN-L)
- 1550-8528
- OpenAlex
- W4246016694
- Cited by
- 758
- References
- 0
- Citations by year
- 2026: 9 · 2025: 6 · 2024: 11 · 2023: 11 · 2022: 15 · 2021: 14 · 2020: 14 · 2019: 19 · 2018: 16 · 2017: 23 · 2016: 32 · 2015: 36 · 2014: 50 · 2013: 45 · 2012: 42
- FWCI
- 10.98
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Obesity Research (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Social Sciences › Psychology › Clinical Psychology › Eating Disorders and Behaviors
- Keywords
- dexfenfluramine, fenfluramine, valvular heart disease, phentermine, sibutramine, orlistat, weight loss, weight loss maintenance, obesity pharmacotherapy, drug safety
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
